National Health (Immunisation Program – Designated Vaccines) Variation Determination 2017 (No. 2) (Cth)

National Health (Immunisation Program – Designated Vaccines) Variation Determination 2017 (No. 2)

National Health Act 1953

I, Masha Somi, delegate of the Minister for Health, make this Determination under subsection 9B(2) of the National Health Act 1953.

Dated 12 September 2017

Dr Masha Somi

Assistant Secretary

Immunisation Branch

Office of Health Protection

Department of Health

1. Name of Determination

This Determination is the National Health (Immunisation Program – Designated Vaccines) Variation Determination 2017 (No. 2).

1. Commencement

This Determination commences on 18 September 2017.

3Authority

This Determination is made under subsection 9B(2) of the National Health Act 1953.          

1. Variation of National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No. 1)

The Schedule varies the National Health (Immunisation Program – Designated     Vaccines) Determination 2014 (No. 1).

Schedule

[1] Subsection 7(11)

Omit, substitute:

(11)   For each one of items 101, 102, 106, 107, 108, 202, 211, 212, 213, 214, 215, 216, 217, 218, 218A and 219 of Schedule 1, in addition to the circumstances specified in the item in which the designated vaccine may be provided to an individual, the vaccine may be provided to an individual if:

(a)    the individual is 10 years of age or older but less than 20 years of age; and

(b)    the individual did not receive the vaccine at an age mentioned in the circumstances of the item or in accordance with the circumstances described at subsection 7(10).

[2] After item 218 in Schedule 1, Part 2

Insert

218A Vaccine Human papillomavirus (HPV) (9-valent) Circumstances Vaccine may be provided to a person who is at least 12 years of age but less than 14 years of age. Gardasil 9 Injection (0.5mL) Each of the following: (a)     HPV 6 L1 protein - 30μg; (b)     HPV 11 L1 protein - 40μg; (c)     HPV 16 L1 protein - 60μg;  (d)     HPV 18 L1 protein - 40μg; (e)     HPV 31 L1 protein - 20μg;  (f)   HPV 33 L1 protein - 20μg; (g)     HPV 45 L1 protein - 20μg;  (h)     HPV 52 L1 protein - 20μg; (i)   HPV 58 L1 protein - 20μg. 2 doses, with the second dose given 6 to 12 months after the first dose